Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
dc.contributor.author | Natrajan, Rachael | en_US |
dc.contributor.author | Wilkerson, Paul M | en_US |
dc.contributor.author | Marchiò, Caterina | en_US |
dc.contributor.author | Piscuoglio, Salvatore | en_US |
dc.contributor.author | Ng, Charlotte KY | en_US |
dc.contributor.author | Wai, Patty | en_US |
dc.contributor.author | Lambros, Maryou B | en_US |
dc.contributor.author | Samartzis, Eleftherios P | en_US |
dc.contributor.author | Dedes, Konstantin J | en_US |
dc.contributor.author | Frankum, Jessica | en_US |
dc.contributor.author | Bajrami, Ilirjana | en_US |
dc.contributor.author | Kopec, Alicja | en_US |
dc.contributor.author | Mackay, Alan | en_US |
dc.contributor.author | A'hern, Roger | en_US |
dc.contributor.author | Fenwick, Kerry | en_US |
dc.contributor.author | Kozarewa, Iwanka | en_US |
dc.contributor.author | Hakas, Jarle | en_US |
dc.contributor.author | Mitsopoulos, Costas | en_US |
dc.contributor.author | Hardisson, David | en_US |
dc.contributor.author | Lord, Christopher J | en_US |
dc.contributor.author | Kumar‐sinha, Chandan | en_US |
dc.contributor.author | Ashworth, Alan | en_US |
dc.contributor.author | Weigelt, Britta | en_US |
dc.contributor.author | Sapino, Anna | en_US |
dc.contributor.author | Chinnaiyan, Arul M | en_US |
dc.contributor.author | Maher, Christopher A | en_US |
dc.contributor.author | Reis‐filho, Jorge S | en_US |
dc.date.accessioned | 2014-05-21T18:03:26Z | |
dc.date.available | WITHHELD_13_MONTHS | en_US |
dc.date.available | 2014-05-21T18:03:26Z | |
dc.date.issued | 2014-04 | en_US |
dc.identifier.citation | Natrajan, Rachael; Wilkerson, Paul M; Marchiò, Caterina ; Piscuoglio, Salvatore; Ng, Charlotte KY; Wai, Patty; Lambros, Maryou B; Samartzis, Eleftherios P; Dedes, Konstantin J; Frankum, Jessica; Bajrami, Ilirjana; Kopec, Alicja; Mackay, Alan; A'hern, Roger; Fenwick, Kerry; Kozarewa, Iwanka; Hakas, Jarle; Mitsopoulos, Costas; Hardisson, David; Lord, Christopher J; Kumar‐sinha, Chandan ; Ashworth, Alan; Weigelt, Britta; Sapino, Anna; Chinnaiyan, Arul M; Maher, Christopher A; Reis‐filho, Jorge S (2014). "Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast." The Journal of Pathology 232(5): 553-565. | en_US |
dc.identifier.issn | 0022-3417 | en_US |
dc.identifier.issn | 1096-9896 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/106752 | |
dc.description.abstract | Micropapillary carcinoma ( MPC ) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations ( CNAs ) distinct from that of grade‐ and oestrogen receptor ( ER )‐matched invasive carcinomas of no special type ( IC‐NSTs ). The aims of this study were to determine whether MPCs are underpinned by a recurrent fusion gene(s) or mutations in 273 genes recurrently mutated in breast cancer. Sixteen MPCs were subjected to microarray‐based comparative genomic hybridization ( aCGH ) analysis and Sequenom OncoCarta mutation analysis. Eight and five MPCs were subjected to targeted capture and RNA sequencing, respectively. aCGH analysis confirmed our previous observations about the repertoire of CNAs of MPCs . Sequencing analysis revealed a spectrum of mutations similar to those of luminal B IC‐NSTs , and recurrent mutations affecting mitogen‐activated protein kinase family genes and NBPF10 . RNA ‐sequencing analysis identified 17 high‐confidence fusion genes, eight of which were validated and two of which were in‐frame. No recurrent fusions were identified in an independent series of MPCs and IC‐NSTs . Forced expression of in‐frame fusion genes ( SLC2A1–FAF1 and BCAS4–AURKA ) resulted in increased viability of breast cancer cells. In addition, genomic disruption of CDK12 caused by out‐of‐frame rearrangements was found in one MPC and in 13% of HER2 ‐positive breast cancers, identified through a re‐analysis of publicly available massively parallel sequencing data. In vitro analyses revealed that CDK12 gene disruption results in sensitivity to PARP inhibition, and forced expression of wild‐type CDK12 in a CDK12 ‐null cell line model resulted in relative resistance to PARP inhibition. Our findings demonstrate that MPCs are neither defined by highly recurrent mutations in the 273 genes tested, nor underpinned by a recurrent fusion gene. Although seemingly private genetic events, some of the fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer therapeutic opportunities. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. | en_US |
dc.publisher | John Wiley & Sons, Ltd | en_US |
dc.subject.other | PARP Inhibitors | en_US |
dc.subject.other | Breast Cancer | en_US |
dc.subject.other | Micropapillary | en_US |
dc.subject.other | RNA Sequencing | en_US |
dc.subject.other | Fusion Transcripts | en_US |
dc.subject.other | Somatic Mutation Profiling | en_US |
dc.subject.other | CDK12 | en_US |
dc.title | Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pathology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/106752/1/path4325.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/106752/2/path4325-sup-0001-AppendixS1.pdf | |
dc.identifier.doi | 10.1002/path.4325 | en_US |
dc.identifier.source | The Journal of Pathology | en_US |
dc.identifier.citedreference | Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903 – 2904. | en_US |
dc.identifier.citedreference | Edgren H, Murumagi A, Kangaspeska S, et al. Identification of fusion genes in breast cancer by paired‐end RNA‐sequencing. Genome Biol 2011; 12: R6. | en_US |
dc.identifier.citedreference | Natrajan R, Mackay A, Lambros MB, et al. A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers. J Pathol 2012; 227: 29 – 41. | en_US |
dc.identifier.citedreference | Banerji S, Cibulskis K, Rangel‐Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405 – 409. | en_US |
dc.identifier.citedreference | The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61 – 70. | en_US |
dc.identifier.citedreference | Robinson DR, Kalyana‐Sundaram S, Wu YM, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med 2011; 17: 1646 – 1651. | en_US |
dc.identifier.citedreference | Ha KC, Lalonde E, Li L, et al. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1‐mutated breast cancers and cell lines. BMC Med Genomics 2011; 4: 75. | en_US |
dc.identifier.citedreference | Kalyana‐Sundaram S, Shankar S, Deroo S, et al. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 2012; 14: 702 – 708. | en_US |
dc.identifier.citedreference | Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562 – 573. | en_US |
dc.identifier.citedreference | Marchio C, Natrajan R, Shiu KK, et al. The genomic profile of HER2 ‐amplified breast cancers: the influence of ER status. J Pathol 2008; 216: 399 – 407. | en_US |
dc.identifier.citedreference | Hernandez L, Wilkerson PM, Lambros MB, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection. J Pathol 2012; 227: 42 – 52. | en_US |
dc.identifier.citedreference | Coe BP, Ylstra B, Carvalho B, et al. Resolving the resolution of array CGH. Genomics 2007; 89: 647 – 653. | en_US |
dc.identifier.citedreference | Gunnarsson R, Staaf J, Jansson M, et al. Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia – a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697 – 711. | en_US |
dc.identifier.citedreference | Tan DS, Lambros MB, Natrajan R, et al. Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737 – 754. | en_US |
dc.identifier.citedreference | Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal‐like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575 – 589. | en_US |
dc.identifier.citedreference | Duprez R, Wilkerson PM, Lacroix‐Triki M, et al. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol 2012; 226: 427 – 441. | en_US |
dc.identifier.citedreference | Wagle N, Berger MF, Davis MJ, et al. High‐throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82 – 93. | en_US |
dc.identifier.citedreference | De Mattos‐Arruda L, Bidard FC, Won HH, et al. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2013 (Epub ahead of print); DOI: 10.1016/j.molonc.2013.10.006. | en_US |
dc.identifier.citedreference | DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next‐generation DNA sequencing data. Nature Genet 2011; 43: 491 – 498. | en_US |
dc.identifier.citedreference | Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213 – 219. | en_US |
dc.identifier.citedreference | Ding J, Bashashati A, Roth A, et al. Feature‐based classifiers for somatic mutation detection in tumour–normal paired sequencing data. Bioinformatics 2012; 28: 167 – 175. | en_US |
dc.identifier.citedreference | McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res 2010; 20: 1297 – 1303. | en_US |
dc.identifier.citedreference | Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568 – 576. | en_US |
dc.identifier.citedreference | Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nature Biotechnol 2011; 29: 24 – 26. | en_US |
dc.identifier.citedreference | Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease‐defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011; 3: 98ra82. | en_US |
dc.identifier.citedreference | Wilkerson PM, Dedes KJ, Wetterskog D, et al. Functional characterization of EMSY gene amplification in human cancers. J Pathol 2011; 225: 29 – 42. | en_US |
dc.identifier.citedreference | Dedes KJ, Wetterskog D, Mendes‐Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75. | en_US |
dc.identifier.citedreference | Horlings HM, Weigelt B, Anderson EM, et al. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257 – 269. | en_US |
dc.identifier.citedreference | Ellis MJ, Ding L, Shen D, et al. Whole‐genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353 – 360. | en_US |
dc.identifier.citedreference | Nik‐Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979 – 993. | en_US |
dc.identifier.citedreference | Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple‐negative breast cancers. Nature 2012; 486: 395 – 399. | en_US |
dc.identifier.citedreference | Doublier S, Belisario DC, Polimeni M, et al. HIF‐1 activation induces doxorubicin resistance in MCF7 3‐D spheroids via P‐glycoprotein expression: a potential model of the chemo‐resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012; 12: 4. | en_US |
dc.identifier.citedreference | Vasmatzis G, Johnson SH, Knudson RA, et al. Genome‐wide analysis reveals recurrent structural abnormalities of TP63 and other p53‐related genes in peripheral T‐cell lymphomas. Blood 2012; 120: 2280 – 2289. | en_US |
dc.identifier.citedreference | Mao X, Boyd LK, Yanez‐Munoz RJ, et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res 2011; 1: 604 – 617. | en_US |
dc.identifier.citedreference | Shiu KK, Wetterskog D, Mackay A, et al. Integrative molecular and functional profiling of ERBB2‐amplified breast cancers identifies new genetic dependencies. Oncogene 2013 (Epub ahead of print); DOI: 10.1038/onc.2012.625. | en_US |
dc.identifier.citedreference | Blazek D, Kohoutek J, Bartholomeeusen K, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011; 25: 2158 – 2172. | en_US |
dc.identifier.citedreference | Menges CW, Altomare DA, Testa JR. FAS‐associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle 2009; 8: 2528 – 2534. | en_US |
dc.identifier.citedreference | Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786: 60 – 72. | en_US |
dc.identifier.citedreference | Zang ZJ, Ong CK, Cutcutache I, et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011; 71: 29 – 39. | en_US |
dc.identifier.citedreference | Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa‐cell tumors of the ovary. N Engl J Med 2009; 360: 2719 – 2729. | en_US |
dc.identifier.citedreference | Wetterskog D, Lopez‐Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers. J Pathol 2012; 226: 84 – 96. | en_US |
dc.identifier.citedreference | Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand‐binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474 – 1481. | en_US |
dc.identifier.citedreference | Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER‐2/neu status of breast cancers using the United States Food and Drug Administration‐approved scoring system. J Clin Oncol 1999; 17: 1983 – 1987. | en_US |
dc.identifier.citedreference | Mackay A, Tamber N, Fenwick K, et al. A high‐resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 481 – 498. | en_US |
dc.identifier.citedreference | Natrajan R, Lambros MB, Rodriguez‐Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711 – 2722. | en_US |
dc.identifier.citedreference | Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing‐based copynumber variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 2011; 27: 2648 – 2654. | en_US |
dc.identifier.citedreference | Brough R, Frankum JR, Sims D, et al. Functional viability profiles of breast cancer. Cancer Discov 2011; 1: 260 – 273. | en_US |
dc.identifier.citedreference | Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast ( 4th edn ). IARC Press: Lyon, 2012. | en_US |
dc.identifier.citedreference | Marchio C, Iravani M, Natrajan R, et al. Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301 – 315. | en_US |
dc.identifier.citedreference | Marchio C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215: 398 – 410. | en_US |
dc.identifier.citedreference | Weigelt B, Geyer FC, Reis‐Filho JS. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192 – 208. | en_US |
dc.identifier.citedreference | Weigelt B, Reis‐Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009; 6: 718 – 730. | en_US |
dc.identifier.citedreference | Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740 – 18744. | en_US |
dc.identifier.citedreference | Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6–NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367 – 376. | en_US |
dc.identifier.citedreference | Bertucci F, Orsetti B, Negre V, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27: 5359 – 5372. | en_US |
dc.identifier.citedreference | Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type. J Pathol 2010; 220: 45 – 57. | en_US |
dc.identifier.citedreference | Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal‐like breast cancer metastasis and xenograft. Nature 2010; 464: 999 – 1005. | en_US |
dc.identifier.citedreference | Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809 – 813. | en_US |
dc.identifier.citedreference | Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005 – 1010. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.